Anti-CCP can be detected early in the disease's progression. Improving diagnostic testing means that rheumatoid arthritis can be treated at an earlier stage.
Roche conducts intensive research into the causes and progression of inflammatory diseases. Based on the results of this research, we can develop pharmaceuticals that really benefit patients. To treat rheumatoid arthritis, for example, we developed biopharmaceuticals that specifically intervene in the molecular process behind the development of the diseases, without weakening the immune system as a whole. The treatment alleviates pain and holds the disease in check.
The earlier that rheumatoid arthritis can be diagnosed, the greater the chances are of preventing joint damage and avoiding the risk of patients losing mobility. Roche has developed a reliable diagnostic test for early detection.
Rheumatoid arthritis – a diagnostic test for early detection and treatment selection
The anti-CCP test enables a diagnosis of rheumatoid arthritis during the earliest stages of the disease. As a result, this chronic inflammatory auto-immune disease can be stopped in its tracks as early as possible.
For patients who do not respond to basic treatment or to treatment with TNF-alpha inhibitors, the anti-CCP test allows doctors to recommend a different course of treatment. If the test is positive, treatment with MabThera is likely to be successful. The compound MabThera, developed by Roche, neutralizes the harmful effects of the white blood cells that are produced by the extreme response of the immune system in auto-immune diseases.
The anti-CCP test measures whether the patient's blood contains antibodies against citrullinated proteins. These proteins, in which the amino acid arginine has been converted into citrulline, play a key role in the development of rheumatoid arthritis.